The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients

Thrombosis Research

Volumn 122, Issue 3, 2008, Pages 328-335

  Pawlak, Krystyna ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Atherosclerosis; CC chemokines; Haemodialysis; Peritoneal dialysis; uPA suPAR system

Indexed keywords

ALBUMIN; BETA CHEMOKINE; CREATININE; HEMOGLOBIN; MACROPHAGE INFLAMMATORY PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL; UROKINASE RECEPTOR;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; CAROTID ARTERY DISEASES; CHEMOKINE CCL2; CHEMOKINE CCL3; CHEMOKINE CCL4; CHEMOKINE CCL5; CHEMOKINES, CC; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CELL SURFACE; RENAL DIALYSIS; SOLUBILITY; UREMIA; URINARY PLASMINOGEN ACTIVATOR;

EID: 45849091522     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.10.017     Document Type: Article

References (23)

1. Amann K., Ritz C., Adamczak M., and Ritz E. Why is coronary heart disease of uraemic patients so frequent and so devastating?. Nephrol Dial Transplant 18 (2003) 631-640
2. Libby P. Changing concepts of atherogenesis. J Intern Med 247 (2000) 349-358
3. Steins M.B., Padro T., Schwaenen C., Ruiz S., Mesters R.M., Berdel W.E., et al. Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions. Blood Coagul Fibrinolysis 15 (2004) 383-391
4. Gyetko M.R., Todd R.F., Wilkinson C.C., and Sitrin R.G. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 93 (1994) 1380-1387
5. Sitrin R.G., Togg R.F., Albrecht E., and Gyetko M.R. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 97 (1996) 1942-1951
6. Yebra M., Parry G.C.N., Stromblad S., Mackman N., Rosenberg S., Mueller B.M., et al. Requirement of receptor-bound urokinase-type plasminogen activator for integrin alphavbeta5-directed cell migration. J Biol Chem 271 (1996) 29393-29399
7. Rollins B.J. Chemokines. Blood 90 (1997) 909-928
8. Peters W., and Charo I.F. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr Opin Lipidol 12 (2001) 175-180
9. Wilcox J.N., Nelken N.A., Coughlin S.R., Gordon D., and Schall T.J. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1 (1994) S3-S10
10. Pawlak K., Naumnik B., Brzósko S., Pawlak D., and Myśliwiec M. Oxidative stress-a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients. Am J Nephrol 24 (2004) 154-161
11. Pawlak K., Pawlak D., Brzosko S., and Mysliwiec M. Carotid atherosclerosis is associated with enhanced β-chemokine levels in patients on continuous ambulatory peritoneal dialysis. Atherosclerosis 186 (2006) 146-151
12. Pawlak K., Pawlak D., and Mysliwiec M. Oxidative stress effects fibrinolytic system in dialysis uraemic patients. Thromb Res 117 (2006) 517-522
13. Mysliwiec K., Pawlak D., and Pawlak M. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity. Thromb Res 119 (2007) 475-480
14. Nakayama M., Yoshida E., Sugiki M., Anai K., Maruyama M., and Maruyama H. Up-regulation of the urokinase-type plasminogen activator receptor by monocyte chemotactic proteins. Blood Coagul Fibrinolysis 13 (2002) 383-391
15. Boyle M.D.P., Chiodo V.A., Lawman M.J.P., Gee A.P., and Young M. Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol 139 (1987) 169-174
16. Wainberg M.A., Israel E., and Margolese R.G. Further studies on the mitogenic and immune-modulating effects of plasminogen activator. Immunology 45 (1982) 715-720
17. May A.E., Schmidt R., Kanse S.M., Chavakis T., Chavakis R.W., Chavakis A., et al. Urokinase receptor surface expression regulates monocyte adhesion in acute myocardial infarction. Blood 100 (2002) 3611-3617
18. Kirchheimer J.C., and Remold H.G. Endogenous receptor-bound urokinase mediates tissue invasion of human monocytes. J Immunol 143 (1989) 2634-2639
19. Montuori N., Salzano S., Rossi G., and Ragno P. Urokinase-type plasminogen activator up-regulates the expression of its cellular receptor. FEBS Lett 476 (2000) 166-170
20. Sitrin R.G., Todd R.F., Mizukami I.F., Gross T.J., Shollenberg S.B., and Gyetko M.R. Cytokine-specific regulation of urokinase receptor (CD87) expression by U937 mononuclear phagocytes. Blood 84 (1994) 1268-1275
21. Chavakis T., Kanse S.M., Yutzy B., Lijnen H.R., and Preissner K.T. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complex. Blood 91 (1998) 2305-2312
22. Wei Y., Lukashev M., Simon D.I., Bodary S.C., Rosenberg S., Doyle M.V., et al. Regulation of integrin function by urokinase receptor. Science 273 (1996) 1551-1555
23. Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E., and Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 16 (1997) 7279-7286